How past alcohol or drug use affects detection and treatment of non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational qualitative project will conduct semi-structured interviews (30–60 minutes) with adults diagnosed with non-small cell lung cancer who had alcohol or other substance use disorders in the prior 10 years, with optional follow-up focus groups to review preliminary findings. Participants will be recruited at Keck/USC, Los Angeles General Medical Center, and Norris Comprehensive Cancer Center and interviews will be conducted in English or Spanish. The aim is to identify social facilitators and barriers that affect timely detection and receipt of curative-intent treatment. Results will be used to inform outreach, care coordination, and possible interventions to improve access and outcomes for this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* \* Adults ≥ 18 years of age

  * Histopathologic or cytologic diagnosis of thoracic cancers, including lung and esophageal
  * Received or receiving curative intent treatment (e.g. surgery, radiation therapy, systemic therapy)
  * Ability to understand and the willingness to sign a written informed consent
  * English or Spanish speaking. Due to need to conduct semi-structured interviews which can develop into free-flowing conversations we need both participant and interviewer to be fluent

Exclusion Criteria:

* Patients with cognitive disability unable to maintain 30-60 minute conversation

Where it's running

• Los Angeles General Medical Center
  Los Angeles, California, United States Recruiting
• USC / Norris Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Brooks V Udelsman — University of Southern California

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LUCINAE Registry: Thoracic Cancers in Pregnancy

  This international registry collects data to see how thoracic cancers, including lung cancer, are managed and what outcomes look like for pregnant people and their babies.

  Recruiting at 4 sites Oncology Institute of Southern Switzerland · Baden and 3 other locations · NCT07699861

• Heart-friendly medicines to protect chest-area cancer patients from radiation damage

  This Phase 2 trial tests whether taking atorvastatin and lisinopril can reduce heart damage in adults with chest-area cancers who receive radiation therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07685938

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

• Atezolizumab after surgery to prevent NSCLC from coming back

  This trial tests whether giving atezolizumab (with or without hyaluronidase) for one year after complete surgery helps prevent NSCLC from returning compared with observation.

  Recruiting at 145 sites Phase 3 National Cancer Institute (NCI) · Anaheim, California and 144 other locations · NCT07388524

• Patient experiences and preferences for IV versus subcutaneous immunotherapy in non-small cell lung cancer

  This survey asks people with non-small cell lung cancer who are receiving immune checkpoint inhibitors whether they prefer IV treatment or subcutaneous injections at the hospital or at home.

  Recruiting at 2 sites University of Southern California · Los Angeles, California and 1 other locations · NCT07339254

• Telisotuzumab vedotin combined with osimertinib for progressive, incurable non-small cell lung cancer

  This trial tests whether adding the antibody-drug telisotuzumab vedotin to ongoing osimertinib can shrink tumors or slow growth in adults with progressive, incurable non-small cell lung cancer who have EGFR mutations.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07323641

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.